CRBP News and Press, Corbus Pharmaceuticals Holdings Inc. From 01/09/24

CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironment Phase 1 clinical study set to commence H1 2024 Pre-clinical data presented demonstrates robust anti-tumor activity in solid tumor models NORWOOD, Mass., Jan. 09, 2024 (G...

NORWOOD, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced that the Phase 1, first-in-human clinical data from a dose esc...

2023-11-30 12:17:22 ET More on AbbVie, ImmunoGen, etc. AbbVie: Get Ready For More Painful Downside AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time Biggest stock movers today: Sna...

Corbus Pharmaceuticals Holdings Inc. (CRBP) is expected to report $-2.06 for Q3 2023

2023-11-07 09:51:33 ET More on Corbus Pharmaceuticals Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for Corbus Pharmaceuticals For further details see: Corbus Pharma...

Data from dose escalation study for CRB-701, a Nectin-4 ADC to treat solid tumors, on track for release in early 2024 along with start of U.S./EU Study IND Submission for CRB-601, an αvβ8 Monoclonal Antibody to treat solid tumors, on track for Q4 2023 Pre-clini...

NORWOOD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal ant...

CRB-913 is a novel highly peripherally restricted CB1 inverse agonist with potent monotherapy efficacy in DIO mouse model Weight loss and related outcomes markedly enhanced in combination with tirzepatide, semaglutide or liraglutide NORWOOD, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Corb...

CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotin Early dose escalation clinical data supports differentiating features established pre-clinically The company on schedule to initiate its US study in Q1-2024 NORWOOD, Mass., Oct. 16...

NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the development of a next generation Nectin-4 anti...